ΠΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΡΠ΅ ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ Π΄Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΈ Π΄Π΅ΡΠ΅ΠΊΡΠΈΠΈ ΠΌΡΡΠ°ΡΠΈΠΉ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π
ΠΠΏΠ΅ΡΠ²ΡΠ΅ ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅ΡΡΡ ΡΠ½ΠΈΠ²Π΅ΡΡΠ°Π»ΡΠ½ΡΠΉ ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΈ ΠΏΡΠΎΡΡΠΎΠΉ ΡΠΏΠΎΡΠΎΠ± ΠΊΠΎΠ½ΡΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ° Π΄Π»Ρ ΠΎΠ΄Π½ΠΎΡΡΠ°Π΄ΠΈΠΉΠ½ΠΎΠΉ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ¦Π . ΠΠΎΠΊΠ°Π·ΡΠ²Π°Π΅ΡΡΡ, ΡΡΠΎ ΠΌΠ΅ΡΠΎΠ΄ Π°Π»Π»Π΅Π»Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠ¦Π Π΄Π»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΌΡΡΠ°ΡΠΈΠΉ Π² Π²ΠΈΡΡΡΠ½ΠΎΠΌ Π³Π΅Π½ΠΎΠΌΠ΅ ΠΏΡΠΈΠΌΠ΅Π½ΠΈΠΌ Π² Π΄ΠΈΠ°ΠΏΠ°Π·ΠΎΠ½Π΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΉ ΠΠΠ ΠΎΡ 104 Π΄ΠΎ 107 Π³Π΅Π½ΠΎΠΌ/ΠΌΠ». ΠΡΠΈΡΠ΅ΠΌ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ Π°Π»Π»Π΅Π»Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΠ¦Π Π² ΡΠΊΠ°Π·Π°Π½Π½ΡΡ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΎΠ½Π½ΡΡ ΠΏΡΠ΅Π΄Π΅Π»Π°Ρ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΎΡΠ΅Π½ΠΈΠ²Π°ΡΡ Π΄ΠΎΠ»Ρ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- 1. ΠΠΠΠΠ ΠΠΠ’ΠΠ ΠΠ’Π£Π Π«
- 1. 1. ΠΠΈΡΡΡΠ³Π΅ΠΏΠ°ΡΠ³Π°Π
- 1. 1. 1. ΠΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ Π²ΠΈΡΡΡΠ½ΡΡ ΡΠ°ΡΡΠΈΡ
- 1. 1. 2. ΠΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π³Π΅Π½ΠΎΠΌΠ° ΠΈ ΠΏΡΠΎΠ΄ΡΠΊΡΡ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅Π½ΠΎΠ²
- 1. 1. 3. ΠΠΈΠ·Π½Π΅Π½Π½ΡΠΉ ΡΠΈΠΊΠ» Π²ΠΈΡΡΡΠ°
- 1. 1. 4. ΠΡΡΠ°ΡΠΈΠΎΠ½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π³Π΅Π½ΠΎΠΌΠ° Π²ΠΈΡΡΡΠ°
- 1. 1. 4. 1. Precore-ΠΌΡΡΠ°ΡΠΈΡ Π² Π‘-Π³Π΅Π½Π΅
- 1. 1. 4. 2. YMDD-ΠΌΡΡΠ°ΡΠΈΡ Π² Π -Π³Π΅ΠΏΠ΅
- 1. 1. 5. ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π²ΠΈΡΡΡΠ° Π² ΠΊΡΠΎΠ²ΠΈ
- 1. 2. ΠΠ¦Π -Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΊΠ° Π²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π
- 1. 2. 1. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½Π°Ρ ΠΠ¦Π -Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°
- 1. 2. 2. ΠΠ¦Π -Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°precore- ΠΈ YMDD-ΠΌΡΡΠ°ΡΠΈΠΉ
- 1. 1. ΠΠΈΡΡΡΠ³Π΅ΠΏΠ°ΡΠ³Π°Π
- 2. 1. Π‘ΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π±Π°Π½ΠΊΠ° ΡΡΠ²ΠΎΡΠΎΡΠΎΠΊ
- 2. 2. ΠΡΡΠΎΡΠΏΡΠ°ΠΉΠΌΠ΅ΡΠΎΠ²Π΄Π»ΡΠΠ¦Π
- 2. 3. ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½Π°Ρ ΡΠ΅ΠΏΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ
- 2. 4. ΠΠ»Π»Π΅Π»Ρ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½Π°Ρ ΡΠ΅ΠΏΠ½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ
- 2. 5. ΠΠ΅Π»Ρ-ΡΠ»Π΅ΠΊΡΡΠΎΡΠΎΡΠ΅Π·Π°ΠΌΠΏΠ»ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉΠΠΠ
- 2. 6. ΠΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ°
- 2. 7. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 2. 8. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΠΠ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ¦Π
- 3. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ° Π΄Π»Ρ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ¦Π
- 3. 2. ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΠΠ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΠ¦Π
- 3. 3. ΠΠ΅ΡΠ΅ΠΊΡΠΈΡ YMDD/precore-ΠΌΡΡΠ°ΡΠΈΠΉ Π² ΠΠΠ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠΌΠΌΠΎΡΠΎΠ² Π. Π. ΠΠ΅ΠΏΠ°ΡΠΈΡ Π. ΠΠ½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ. ΠΠΎΠ»ΡΡΠΎΠ²ΠΎ: ΠΠ½ΡΡΠΈΡΡΡ ΡΡΠ΅Π΄ΡΡΠ² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ ΠΠΠ «ΠΠ΅ΠΊΡΠΎΡ-ΠΠ΅ΡΡ», 1998.
- ΠΠΏΡΠΎΡΠΈΠ½Π° Π.Π. ΠΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ Π² ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ²: ΠΎΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ½ΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π // Π ΡΡΡΠΊ. ΠΌΠ΅Π΄. ΠΆΡΡΠ½. 1996. — Π’. 4. — № 3. — Π‘. 174−177.
- ΠΠ°Π»Π°ΡΠ½ Π.Π‘., ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π. Π. ΠΠ½ΡΠΈΠΊΠ»ΠΎΠΏΠ΅Π΄ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ»ΠΎΠ²Π°ΡΡ -Π²ΠΈΡΡΡΠ½ΡΠ΅ Π³Π΅ΠΏΠ°ΡΠΈΡΡ. ΠΠ·Π΄. 2-Π΅, ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ΅ ΠΈ Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΠΎΠ΅. Π.: ΠΠΌΠΈΠΏΡΠ΅ΡΡ, 1999.
- ΠΠ»ΡΠΈΠ½Π° Π.Π., ΠΠΎΠ²ΠΎΡΡΠ½ Π. Π., ΠΠ²Π°Π½ΠΈΠΊΠΎΠ² Π. Π., Π‘ΡΡΠΊΠΈΠ½ Π. Π., ΠΠ΅ΡΡΡ ΠΎΠ²Π° Π‘. Π. Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²ΠΈΡΡΡΠ½ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ. ΠΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΠΎΡΠΎΠ±ΠΈΠ΅ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ. Π.: ΠΠ°ΡΡΠ½ΠΎ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠΈΡΠΌΠ° «ΠΠΈΡΠ΅Ρ », 2001.
- ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ½ΠΊΠΎΠ³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡ. Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ / ΠΠΎΠ΄ ΡΠ΅Π΄. Π. Π. ΠΠΎΠ»ΠΊΠΎΠ²ΠΎΠΉ.-Π.:ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2001. 576 Ρ.
- ΠΠ»ΠΈΠΌΠ΅Π½ΠΊΠΎ Π‘.Π. ΠΠΈΠΎΠ»ΠΎΠ³ΠΈΡ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π // ΠΡΠ»Π»Π΅ΡΠ΅Π½Ρ «ΠΠ°ΠΊΡΠΈΠ½Π°ΡΠΈΡ». 1999. — № 4. — Π‘. 39−44.
- ΠΠΎΠΌΡΠ½Π°Π»ΠΈΠ΅Π² Π.Π’., ΠΠΎΠ²ΠΎΡΡΠ½ Π. Π. ΠΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² ΠΠΠ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΉ ΡΠ»ΡΠΆΠ±Π΅. Π§Π°ΡΡΡ 2 (Π»Π΅ΠΊΡΠΈΡ). // ΠΠ»ΠΈΠ½, Π»Π°Π±. Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ°. — 2000. № 5. — Π‘.25−37
- ΠΠ΅ΡΠ΅ΡΠΎΠ² Π‘.Π. ΠΠΈΡΡΡΠ½ΡΠ΅ Π³Π΅ΠΏΠ°ΡΠΈΡΡ // Π‘ΠΠ. 1997. — № 2. — Π‘.35−43.
- ΠΠΈΡΠΊΠΎΠ²ΡΠΊΠ°Ρ Π.Π. Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠ΅ΡΡ-ΡΠΈΡΡΠ΅ΠΌΡ, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎΠΉ Π½Π° ΠΌΠ΅ΡΠΎΠ΄Π΅ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ, Π΄Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΠΠ Π²ΠΈΡΡΡΠ° Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ. // ΠΠ΅ΡΡΠ½ΠΈΠΊ Π ΠΠΠ£. 2001. — № 2 (17). -Π‘.153.
- Π.Π Π°Ρ ΠΌΠ°Π½ΠΎΠ²Π° Π. Π., ΠΠ΅ΠΌΠΈΠ΄Π΅Π½ΠΊΠΎ Π’. Π., ΠΡΠ·Π½Π΅ΡΠΎΠ² Π. Π., Π‘ΡΠ΅ΠΏΠ°Π½ΠΎΠ²Π°. Π. Π. ΠΡΠΈΠΎΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ΅ΠΏΠ»ΠΈΠΊΠ°ΡΠΈΠ²Π½ΡΡ ΡΠΎΡΠΌ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ² Π ΠΈ Π‘. ΠΠΎΡΠΎΠ±ΠΈΠ΅ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ. Π‘ΠΠ±.: ΠΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠ°Ρ Π°ΠΊΠ°Π΄Π΅ΠΌΠΈΡ-ΠΏΠΎΡΡΠ΄ΠΈΠΏΠ»ΠΎΠΌΠ½ΠΎΠ³ΠΎ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ, 1998.
- Π€Π΅Π²ΡΠ°Π»Π΅Π²Π° Π.Π‘., ΠΠΈΡΠΊΠΎΠ²ΡΠΊΠ°Ρ Π. Π., Π‘ΡΠ΄Π°ΡΠΈΠΊΠΎΠ² Π. Π. ΠΠΎΠ²Π°Ρ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠΎΠ½ΡΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ° Π΄Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. // ΠΡΠΎΠ±Π»Π΅ΠΌΡ Π³Π΅ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π»ΠΈΠ²Π°Π½ΠΈΡ ΠΊΡΠΎΠ²ΠΈ. 2002. — № 1. — Π‘. 89.
- Π€Π΅Π²ΡΠ°Π»Π΅Π²Π° Π.Π‘., ΠΠΈΡΠΊΠΎΠ²ΡΠΊΠ°Ρ Π. Π., Π‘ΡΠ΄Π°ΡΠΈΠΊΠΎΠ² Π. Π. Π‘ΠΏΠΎΡΠΎΠ± ΠΊΠΎΠ½ΡΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π²Π½ΡΡΡΠ΅Π½Π½Π΅Π³ΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ° Π΄Π»Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΠΠ ΠΏΠ°ΡΠΎΠ³Π΅Π½ΠΎΠ² ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΠ°ΡΠ΅Π½Ρ Π½Π° ΠΈΠ·ΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ № 2 194 761. Π.:
- ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠ΅Π΅ΡΡΡ ΠΈΠ·ΠΎΠ±ΡΠ΅ΡΠ΅Π½ΠΈΠΉ Π Π€, 2002.
- Π₯Π΅Π½Π΄Π΅ΡΡΠΎΠ½ Π.Π. ΠΠ°ΡΠΎΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΏΠΈΡΠ΅Π²Π°ΡΠ΅Π½ΠΈΡ. — Π.-Π‘ΠΠ±.: ΠΠΈΠ½ΠΎΠΌ ΠΠ΅Π²ΡΠΊΠΈΠΉ ΠΠΈΠ°Π»Π΅ΠΊΡ, 1997. — Π‘. 182−184.
- Abe A., Inoue Π., Tanaka Π’. et al. Quantitation of hepatitis Π virus genomic DNA by real-time detection PCR // J. Clin. Microbiol. 1999. -37: 2899−2903.
- Allen M.I., Gauthier J., Deslauriers M. et al. Two Sensitive PCR-Based Methods for Detection of Hepatitis Π Virus Variants Associated with Reduced Susceptibility to Lamivudine // J. Clin. Microbiol. — 1999. -37(10): 3338−3347.
- Arbuthnot P., Capovilla A., Kew M. Putative role of hepatitis Π virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways // J.Gastroenterol.Hepatol. 2000. — 15: 357−368.
- Arts E.J., Wainberg M.A. Mechanisms of Nucleoside Analog Antiviral
- Activity and Resistance During Human Immunodeficiency Virus Reverse Transcription // Antimicrob. Agents Chemother. 1996. — 40(3): 527−540.
- Badur S., Akgun A. Diagnosis of hepatitis Π infections and monitoring of Treatment//J.Clin.Virol. -2001. -21: 229−237.
- Bartholomeusz A, Locarnini S. Hepatitis Π virus mutants and fulminant hepatitis B: fitness plus phenotype // Hepatol. 2001. — 34:432−435.
- Buti M., Sanchez F., Cotrina M. et al. Quantitative Hepatitis Π Virus DNA Testing for the Early Prediction Of the Maintenance of Response during Lamivudine Therapy in Patients With Chronic Hepatitis Π // J.InfectDis. -2001. 183:1277−80.
- Chang C.-N., Skalskis V., Zhou J.H., Chengo Y.-C. Biochemical Pharmacology of (+) — and (-)-2', 3'-Dideoxy-3'- Thiacytidine as Anti-hepatitis Π Virus Agents // J.Biol.Chem. 1992. — 267(31): 22 414−22 420.
- Chu C.J., Hussain M., Lok A.S. Quantitative serum HBV DNA levels during different stages of chronic hepatitis Π infection. // Hepatol. 2002. — 36(6):1408−15.
- Chu CJ., Suk-Fong Lok A. Clinical utility in quantifying serum HBV DNA levels Using PCR assays // J.Hepatol. 2002. -36: 549−551.
- Chu C.-M.,. Yeh C.-T, Lee C.-S. et al. Precore Stop Mutant in HBeAg-Positive Patients with Chronic Hepatitis B: Clinical Characteristics and Correlation with the Course of HBeAg-to-Anti-HBe Seroconversion // J.Clin.Microbiol. 2002. — 40(1): 16−21.
- Clementi M. Quantitative Molecular Analysis of Virus Expression And Replication // J. Clin. Microbiol. 2000. — 38: 2030−2036.
- Clementi M., Bagnarelli P., Manzin A., Menzo S. Competitive Polymerase chain reaction and analysis of viral activity at the molecular level // Genet. Anal. Tech. Appl. 1994. — 11:1−6.
- Conjeevaram H. S., Suk-Fong Lok A. Management of chronic hepatitis Π // J.Hepatol. 2003. — 38: S90-S103.
- Da Silva L.C., Fonseca L.E.P., Carrilho F.J. et al. Predictive factors for response to Lamivudine in chronic hepatitis Π // Rev. Inst. Med. Trop. S. Paulo. 2000. 42(4): 189−196.
- Dai M.S., Lu J.J., Chen Y.C. et al. Reactivation of precore mutant hepatitis Π virus in chemotherapy-treated patients // Cancer. 2001. -92(11): 2927−2932.
- Das K., Xiong X., Yang H. et al. Molecular Modeling and Biochemical Characterization Reveal The Mechanism of Hepatitis Π Virus Polymerase Resistance To Lamivudine (3TC) and Emtricitabine (FTC) // J.Virol. — 2001.-75(10): 4771−4779.
- De Clercq E. Perspectives for the treatment of hepatitis Π virus infections // IntJ.Antimicrob.Agents 1999. — 12: 81−95.
- Doo E., Liang T.J. Molecular Anatomy and Pathophysiologic Implications of Drug Resistance in Hepatitis Π Virus Infection // Gastroenterol.-2001. 120: 1000−1008.
- Drosten C., Weber M., Seifried E., Roth W.K. Evaluation of a new PCR assay with competitive internal control sequence for blood donor screening // Transfusion. 2000. — 40: 718−724.
- Feng J.Y., Johnsoni A.A., Johnsoni K.A., Anderson K.S. Insights into the Molecular Mechanism of Mitochondrial Toxicity by AIDS Drugs //
- J.Biol.Chem. -2001. 276(26): 23 832−23 837.
- Francois G., Kew M., Van Damme P. et al. Mutant hepatitis Π viruses: a matter of academic interest only or a problem with far-reaching implications? // Vaccine. -2001. 19: 3799−3815.
- Gaillard R.K., Barnard J., Lopez V. et al. Kinetic Analysis of Wild-Type and YMDD Mutant Hepatitis Π Virus Polymerases and Effects of Deoxyribonucleotide Concentrations On Polymerase Activity // Antimicrob. Agents Chemother. 2002. — 46(4): 1005−1013.
- Ganem, D., Pollack J.R., and Tavis J. Hepatitis Π virus reverse transcriptase and its many roles in hepadnaviral genomic replication // Infect. Agents Dis. 1994. — 3: 85−93.
- Halpern M.S., Egan J., Mason W.S., England J.M. Viral antigen in endocrine cells of the pancreatic islets and adrenal cortex of Pekin ducks infected with duck hepatitis Π virus // Virus Res. 1984. — 1:213−223.
- Hammerle Π’., Himmelspach M., Dorner F., Falkner F. G. A sensitive PCR assay system for the quantitation of viral Genome equivalents: human immunodeseciency virus type 1 (HIV-1) and hepatitis Π virus (HBV) // Arch. Virol. 1997. — 142: 1297±1306.
- Hendricks D.A., Stowe Π J., Hoo B.S. et al. Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay // Am. J. Clin. Pathol. 1995. — 104: 537−546.
- Hilleman M.R. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications // Vaccine 2001. — 19: 1837−1848.
- Hirsch R.C., Lavine J.E., Chang L.J. et al. Polymerase gene products ofhepatitis Π viruses are required for genomic RNA packaging as well as for reverse transcription // Nature 1990. — 344: 552−555.
- Jardi R., Buti M., Rodriguez-Frias F. et al. Rapid detection of lamivudine-resistant hepatitis Π vims polymerase gene variants // J Virol Methods -1999.-83(1−2): 181−187.
- Kamisango K., Kamogawa C., Sumi M. et al. Quantitative detection of hepatitis Π virus by transcription-mediated amplification and hybridization protection assay // J. Clin. Microbiol. 1999. — 37: 310−314.
- Kessler H.H., Pierer K., Dragon E. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis Π // Clin. Diagn. Virol.-1998.-9:37−43.
- Kessler H.H., Preininger S., Stelzl E. et al. Identification of Different States of Hepatitis Π Virus Infection With a Quantitative PCR Assay // Clin.Diagn.Lab.Immunol. 2000. — 7(2): 298−300.
- Kessler H.H., Stelzl E., Daghofer E. et al. Semiautomated Quantification of Hepatitis Π Virus DNA in a Routine Diagnostic Laboratory // Clin.Diagn.Lab.Immimol. 2000. — 7(5): 853−855.
- Kidd-Ljunggren K., Miyakawa Y., Kidd A. H. Genetic variability in hepatitis Π viruses // J.Gen.Virol. 2002. — 83: 1267−1280.
- Kidd-Ljunggren K., Oberg M., Kidd A. H. Hepatitis Π virus X gene 1751 to 1764 mutations: Implications for HBeAg status and disease // J.Gen.Virol. 1997. — 78: 1469−1478.
- Kidd-Ljunggrena K., Zukerb M., Hofackerc I.L., Kiddd A.H. The Hepatitis Π Virus Pregenome: Prediction of RNA Structure and Implications For the Emergence of Deletions // Intervirol. 2000. -43:154.164.
- Kirby G.M., Batist G., Fotouhi-Ardakani N et al. Allele-specific PSR analysis of p53 codon 249 AGT transversion in liver tissues from patients with viral hepatitis // Int. J. Cancer 1996. — 68(l):21−25.
- Kirishima Π’., Okanoue Π’., Daimon Y. et al Detection of YMDD mutant using a novel sensitive method in chronic Liver disease type Π patients before and during lamivudine treatment // J.Hepatol. 2002. — 37: 259 265.
- Kobayashi S., Ide Π’., Sata M. Detection of YMDD motif mutations in some lamivudine-untreated Asymptomatic hepatitis Π vims carriers // J.Hepatol. 2001. — 34: 584−586.
- Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis Π viruses // J.Cell.Mol.Med. 2002. — 6(1): 113−143.
- Kwok P.-Y. Methods for genotyping single nucleotide polymorphisms // Annu.Rev.Genomics Hum.Genet. 2001. — 2: 235−258.
- Lampertico P., Iavarone M., Lunghi G. et al. Monitoring serum HBV-dna during lamivudine therapy by quantitative PCR assay may predict development of YMDD mutants // J.Hepatol. 2002. — 32(S2): 104.
- Lau G. K, Liang R., Chiu E.K. et al. Hepatic events after bone marrow transplantation in patients with hepatitis Π infection: a case controlled study // Bone Marrow Transplant. 1997. — 19: 795−799.
- Lewin S., Walters Π’., Locarnini S. et al. Hepatitis Π treatment: rational combination chemotherapy Based on viral kinetic and animal model studies // Antiviral Res. 2002. — 55: 381−396.
- Li J., Buckwold V. E., Hon M.-W., Ou J.-H. Mechanism of Suppression of Hepatitis Π Virus Precore RNA Transcription by a Frequent Double Mutation // J.Virol. 1999. — 73(2): 1239−1244.
- Li N., Tan W.G., Tsang R.Y. et al. Quantitative polymerase chain reaction using capillary electrophoresis with laser-induced fluorescence detection: Analysis of duck hepatitis Π // Anal. Bioanal. Chem. 2002. -374: 269−273.
- Liang R.H., Lok A.S., Lai C.L. et al. Hepatitis Π infection in patients with lymphomas // Hematol. Oncol. 1990. — 8: 261−270.
- Liao C.A., Lee C.M., Wu H.C. et al. Lamivudine for the treatment of hepatitis Π virus reactivation following chemotherapy for non-Hodgkin's lymphoma // Br. J. Haematol. 2002. — 116: 166−169.
- Lin O.S., Keeffe E.B. Current treatment strategies for chronic hepatitis Π and Π‘ // Annu. Rev. Med. 2001. — 52: 29−49.
- L0 E.S., Lo Y.M., Fleming K.A. J. Detection of hepatitis Π precore mutant by allele specific polymerase chain reaction // Clin. Pathol. -1992. 45(8): 689−92.
- Locarnini S. Hepatitis Π viral resistance: mechanisms and diagnosis // J.Hepatol. 2003. — 39(S1): 124−132.
- Locarnini S., McMillan J., Bartholomeusz A. The Hepatitis Π Virus and Common Mutants // Semin. Liver Dis. 2003. — 23(1): 5−20.
- Lopez J.L., Mbayed V.A., Telenta P.F.S. et al. «HBe» minus' mutants of hepatitis Π virus. Molecular Characterization and its relation to viral genotypes // Virus Res. 2002. — 87: 41−49.
- Louie M., Louie L., Simor A. E. The role of DNA amplification Technology in the diagnosis of infectious diseases // Can.Med.Assoc, J. -2000. 163(3): 301−9.
- Mackay I.M., Arden K.E., Nitsche A. Real-time PCR in virology // NucLAcids Res. 2002. — 30(6): 1292−1305.
- Maini M.K., Bertoletti A. How can the cellular immune response control hepatitis Π virus replication? // J. Viral Hepat. 2000. — 7: 321−326.
- Mantero G., Zonaro A., Albertini A. et al. DNA enzyme immunoassay: general method for detection products of polymerase chain reaction // Clin Chem. -1991.-37: 442−429.
- Nagata I., Colucci G., Gregorio G. V. et al. The role of HBV DNA quantitative PCR in monitoring the response to Interferon treatment in chronic hepatitis Π virus infection // J.Hepatol. 1999. — 30: 965−969.
- Nakamoto Y., Guidotti L.G., Kuhlen C.V. et al. Immune Pathogenesis of Hepatocellular Carcinoma // J. Exp. Med. 1998. — 188(2): 341−350.
- Nakamura Y., Motokura Π’., Fujita A. et al. Severe hepatitis related to chemotherapy in hepatitis Π virus carriers with hematologic malignancies. Survey in Japan, 1987−1991 // Cancer. 1996. — 78: 2210−2215.
- Niesters H.G. M., de Man R.A., Pas S.D. et al. Identification of a new variant in the YMDD motif Of the hepatitis Π virus polymerase gene selected During lamivudine therapy // J. Med. Microbiol. 2002. — 51: 695−699.
- Nowak M.A., Bonhoeffer S., Hill A M. Viral dynamics in hepatitis Π virus infection // Proc.Natl.Acad.Sci.USA 1996. — 93: 4398−4402.
- Papatheodoridis G.V., Dimou E., Laras A., Papadimitropoulos V., Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease // Hepatol. -2002. 36(1): 219−226.
- Pawlotsky J.M., Bastie A., Lonjon I. et al. What technique should be used for routine detection and quantification of HBV DNA in clinical samples? // J. Virol. Methods. 1997. — 65(2): 245−53.
- Pawlotsky J.-M. HBV DNA assays (methods and practical use) and viral kinetics // EASL International Consensus Conference on Hepatitis B, September 13−14, 2002, Geneva, Switzerland.
- Payan C., Veal N., Crescenzo-Chaigne B. et al. New quantitative assay of hepatitis Π and Π‘ viruses by competitive PCR using alternative internal sequences // J. Virol. Methods. 1997. — 65(2): 299−305.
- Petrosillo N., Ippolito G., Solforosi L. et al. Molecular epidemiology of an outbreak of fulminant hepatitis Π // J. Clin. Microbiol. 2000. — 38(8): 2975−2981.
- Piatak M. J., Luk K.-C., Williams Π., Lifson J. D. Quantitative competitive polymerase chain reaction for accurate Quantitation of HIV DNA and RNA species // Biotechniques. 1993. — 14: 70−81.i
- Picardi M., Pane F., Quintarelli C. et al. Hepatitis Π virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations // Haematol. — 2003. 88: 1296−1303.
- Pollack J.R., Ganem D. An RNA stem-loop structure directs hepatitis Π vims genomic RNA encapsidation // J. Virol. 1993. — 67:3254−3263.
- Prescott L.M. Lamivudine useful against hepatitis B-HIV co-infection // J. Int. Assoc. Physicians AIDS Care. 1995. — 1(5): 34.
- Radziwill G., Tucher W., Schaller H. Mutational analysis of the hepatitis Π virus P gene product: domain structure and RNAseH activity // J.Virol. -1990.-64:613−620.
- Read S.J., Burnett D., Fink C.G. Molecular techniques for clinical diagnostic virology // J. Clin. Pathol. 2000. — 53: 502−506.
- Rizzetto M., Marzano A., Lagget M. Treatment of hepatitis Π e antigen-negative chronic Hepatitis Π with lamivudine // J.Hepatol. — 2003. -39(S1): 168−171.
- Seeger C., Mason W.S. Hepatitis Π Virus Biology // Microbiol.Mol.Biol.Rev. 2000. — 64(1): 51−68.
- Seigneres Π., Aguesse-Germon S., Pichoud C. et al. Duck hepatitis Π virus polymerase gene mutants associated with Resistance to lamivudine have a decreased replication capacity In vitro and in vivo // J.Hepatol. — 2001.-34: 114−122.
- Shibolet O., Ilan Y., Gillis S. et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis Π virus reactivation in hepatitis Π surface antigen carriers // Blood. 2002. — 100: 391−396.
- Schodel F., Peterson D., Zheng J. et al. Structure of hepatitis Π virus core and e-antigen // J.Biol.Chem. 1993. — 2: 1332−1337.
- Silvestri F., Ermacora A., Sperotto A. et al. Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis Π reactivation // Br. J. Haematol. 2000. — 108: 394−6.
- Simmonds P. The origin and evolution of hepatitis viruses in humans // J.Gen.Virol. 2001. — 82: 693−712.
- Stuyver L., Van Geyt C., de Gendt S. et al. Line probe assay for monitoring drug resistance in hepatitis Π virus-infected patients during antiviral therapy // J. Clin. Microbiol. 2000. — 38(2): 702−707.
- Suk-Fong Lok A. Hepatitis Π infection: pathogenesis and management // J.Hepatol. 2000. — 32(S1): 89−97.
- Suzuki F., Suzuki Y., Tsubota A. et al. Mutations of polymerase, precore and core promoter gene in hepatitis Π virus during 5-year, lamivudine therapy // J.Hepatol. 2002. — 37: 824−830.
- Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis Π virus // J.Clin.Virol. 2002. — 25(2): 97 — 106.
- Ustun C., Idilman R., Gurman G. et al. Hematopoietic stem cell transplantation from non-replicative hepatitis Π virus carriers is safe // J.Hepatol. 1999. — 31(2): 202−209.
- Valentine-Thon E., Van Loon A. M., Schirm J. et al. European Proficiency Testing Program for Molecular Detection And Quantitation of Hepatitis Π Virus DNA // J. Clin. Microbiol. 2001. — 39(12): 44 074 412.
- Wang G.H., Seeger C. The reverse transcriptase of hepatitis Π virus acts as a protein primer for viral DNA synthesis // Cell.-1992.-71: 663−670.
- Waris G., Siddiqui A. Regulatory mechanisms of viral hepatitis Π and Π‘ // J. Biosci. 2003. — 28(3): 311−321.
- Waterfall C.M., Eisenthal R., Cobb B.D. Kinetic characterization of primer mismatches in allele-specific PCR: a quantitative assessment // Biochem. Biophys. Res. Commun. 2002. — 299: 715−722.
- Wolters L.M.M., Niesters H.G.M., de Man R.A. Nucleoside analogues for chronic hepatitis Π // EurJ.Gastroenterol.Hepatol. 2001. — 13(12): 1499−506.
- Wu J., Sullivan D.E., Gerber M.A. Quantitative polymerase chain reaction for hepatitis Π virus DNA // J.Virol.Methods. 1994. — 49(3): 331−41.
- Yeh C.-T. Hepatitis Π virus X protein: Searching for a role in hepatocarcinogenesis // J.Gastroenterol.Hepatol. 2000. — 15: 339−341.
- Yeo W., Chan P.K., Zhong S. et al. Frequency of hepatitis Π virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors // J. Med. Virol. 2000. — 62: 299−307.
- Yotsuyanagi H., Hino K., Tomita E. et al. Precore and core promoter mutations, hepatitis Π virus DNA levels And progressive liver injury in chronic hepatitis Π // J.Hepatol. 2002. — 37: 355−363.
- Zanella I., Rossini A., Domenighini D., Albertini A., Cariani E. Quantitative analysis of hepatitis Π virus DNA by real-lime amplification // Eur. J. Clin. Microbiol. Infect. Dis. 2002. — 21(l):22−26.
- Zeuzem S., de Man R.A., Honkoop P. et al. Dynamics of hepatitis Π virus infection in vivo // J. Hepatol. 1997. — 21: 431−436.
- Zoulim F. Assessing Hepatitis Π Virus Resistance In Vitro and Molecular Mechanisms of Nucleoside Resistance // Semin. Liver Dis. —2002.-22(1): 23−31.
- Zoulim F. Hepatitis Π virus resistance to antivirals: clinical implications And management // J.Hepatol. 2003. — 39(S1): 133−138.
- Zoulim F., Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis Π virus polymerase mutations on the outcome of therapy // J.Hepatol. 1998. — 29: 151−168.1. ΠΠΠΠΠΠΠΠ ΠΠΠ‘Π’Π